NattoPharma Names Key Executive:Eric Anderson joins Vitamin K2 Leader to Develop International Markets

4th April 2013, Oslo, Norway.  NattoPharma announces the appointment of Eric Anderson as Senior Vice President (SVP) Global Sales & Marketing.

In the newly established role as SVP, Eric Anderson will direct the global sales & marketing platform for NattoPharma’s proprietary products, including the MenaQ7® brand Vitamin K2 portfolio. In addition Anderson will create and maintain the North American headquarters for NattoPharma, directing strategic sales and marketing activities.

Eric Anderson has been a member of the natural products industry for more than 20 years, during which time he was involved i the introduction of several successful novel ingredients, including Chitosan, CLA and Mk-7 Natural Vitamin K2.

  • Eric Anderson has a long track experience in working in Norwegian companies, establishing sales and activities in USA.
  • 1995 – 1998 work with Natural ASA, with Sales and Marketing – launched Absorbitol® Chitosan and Tonalin® CLA.
  • 1998 – 2004 Managing Partner for Ignite Marketing Group, a PR and marketing firm specializing in nutritional technologies
  • 2003 – 2010 Brand Manager for PL Thomas – establishing MenaQ7™ as the dominating vitamin K2 brand in the US. In parallel he was responsible for launching 5-LOXIN®, a key ingredient in the number on selling joint product in the US.
  • 2010 – 2013 Global VP Sales and Marketing for Aker BioMarine Antarctic, where he was responsible for establishing and staffing the company’s North American offices, with an emphasis on promoting Superba™ brand krill oil.

Executive Chairman of the NattoPharma Board, Frode Marc Bohan, says, “This is a significant reorganization for NattoPharma. We recognize that the US is the leading supplement market and this where MenaQ7® was initially introduced. We are moving the Global Sales & Marketing responsibilities to the US to drive our International efforts. Further, Eric Anderson will build the US Sales team.”

Bohan Continued: “Eric Anderson has been the key in successfully building several US dietary supplement brands – each of them with yearly revenue of more than 100 million USD. It is critical to our long-term success that we develop the largest markets. Now, with our proprietary clinical data and newly-issued patents will provide a basis to build this business. I am very proud that Eric Anderson chose to joining us, he will help to significant to increases shareholders value.”

About MenaQ7 ®
MenaQ7 ® provides natural vitamin K2 as a manufactured fermentation extract. This process generates a highly pure and bio-available form of vitamin K2, menaquinone-7(MK-7). MenaQ7 is the purest and best documented natural vitamin K2 with guaranteed actives and stability, clinical substantiation and several granted patents on cardiovascular health.

About NattoPharma

As a biotechnology-based nutraceutical company, NattoPharma is the worldwide innovator and leader of Vitamin K2 menaquinone-7. Its brand MenaQ7 ® is supported by a global IPR portfolio and revolutionary research substantiating clear efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in an exclusive research and development collaboration with VitaK, University in Maastricht, The Netherlands, working to substantiate the health benefits of natural vitamin K2.

For more information, please contact:

Hogne Vik
CEO, NattoPharma
Cell phone: +47 97 53 53 26
E-mail: hogne.vik@nattopharma.com

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.